Table 2.
Patient characteristics prior to start of the IRD treatment. This table includes 77 patients, however 3 of them who did not complete the first course were excluded from the efficacy analyses
| n (%) | |
|---|---|
| All cases | 77 |
| Had <1 cycles of IRD | 3 (3.8%) |
| Sex (M/F) | 42 (54%)/35 (46%) |
| Number of prior lines (1, 2, 3) | 21 (27%), 27 (35%), 30 (39%) |
| Prior Bortezomib | 76 (99%) |
| Thalidomide | 77 (99%) |
| Transplantation | 45 (58%) |
| Refractory to last line | 2 (2.6%) |
| ISS 1 | 28 (36%) |
| 2 | 9 (11%) |
| 3 | 17 (22%) |
| not performed | 23 (30%) |
| FISH high risk | 21 (27%) |
| standard risk | 33 (43%) |
| not performed | 23 (30%) |
| Mean number of IRD cycles | 8.3 |
| Ixazomib dose reduction required | 9 (11%) |
| Permanent interruption due to AEs | 5 (6.5%) |